NCT05287360View on ClinicalTrials.gov

A Study Comparing Four Different Rivoceranib Tablets in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 30, 2021

Primary Completion Date

March 16, 2022

Study Completion Date

March 24, 2022

Conditions
Healthy
Interventions
DRUG

Rivoceranib

Rivoceranib will be supplied as film-coated tablets for oral administration as 4 different formulations: Formulation 1, 3, and 4 = 250 milligrams; Formulation 2 = 200 milligrams.

Trial Locations (1)

85283

Celerion, Tempe

Sponsors
All Listed Sponsors
lead

Elevar Therapeutics

INDUSTRY

NCT05287360 - A Study Comparing Four Different Rivoceranib Tablets in Healthy Participants | Biotech Hunter | Biotech Hunter